https://www.symptome.ch/threads/noch-ein-wort-zu-immunglobulinen.80957/
Hier noch zwei Studien zu Immunglobulinen bei CFIDS/CFS:
J Psychiatr Res. 1997 Jan-Feb;31(1):133-47.
Double-blind randomized controlled trial to assess the efficacy of intravenous gammaglobulin for the management of chronic fatigue syndrome in adolescents.
Rowe KS.
Department of Paediatrics, University of Melbourne Royal Children's Hospital, Victoria, Australia.
Abstract
A double blind randomized controlled trial was conducted in 71 adolescents aged 11-18 years. Inclusion in the trial required fulfilment of the diagnostic criteria, (Fukuda et al., 1994). Three infusions of 1 gm/kg (max 1 litre of 6 gm/100 ml in 10% w/v maltose solution) were given one month apart. The dummy solution was a 10% w/v maltose solution with 1% albumin of equivalent volume for weight. Efficacy was assessed by difference in a mean functional score including school attendance, school work, social activity and physical activity, between baseline, three months and six months after the final infusion. There was a significant mean functional improvement at the six month follow-up of 70 adolescents with Chronic Fatigue Syndrome of average duration 18 months. There was also a significant improvement for both groups from the beginning of the trial to the six month post infusion follow-up. Adverse effects were common with both solutions but not predictive of response. Neither solution could be identified by recipients.
PMID: 9201655 [PubMed - indexed for MEDLINE]
und
A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome.
Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J.
Department of Infectious Diseases, Prince Henry Hospital, Sydney, Australia.
Comment in:
Am J Med. 1990 Nov;89(5):551-3.
Am J Med. 1991 Oct;91(4):443-4.
Am J Med. 1991 Sep;91(3):320-1.
Am J Med. 1991 Jun;90(6):768.
Abstract
PURPOSE: The chronic fatigue syndrome (CFS) is characterized by profound fatigue, neuropsychiatric dysfunction, and frequent abnormalities in cell-mediated immunity. No effective therapy is known.
PATIENTS AND METHODS: Forty-nine patients (40 with abnormal cell-mediated immunity) participated in a randomized, double-blind, placebo-controlled trial to determine the effectiveness of high-dose intravenously administered immunoglobulin G. The patients received three intravenous infusions of a placebo solution or immunoglobulin at a dose of 2 g/kg/month. Assessment of the severity of symptoms and associated disability, both before and after treatment, was completed at detailed interviews by a physician and psychiatrist, who were unaware of the treatment status. In addition, any change in physical symptoms and functional capacity was recorded using visual analogue scales, while changes in psychologic morbidity were assessed using patient-rated indices of depression. Cell-mediated immunity was evaluated by T-cell subset analysis, delayed-type hypersensitivity skin testing, and lymphocyte transformation with phytohemagglutinin.
RESULTS: At the interview conducted by the physician 3 months after the final infusion, 10 of 23 (43%) immunoglobulin recipients and three of the 26 (12%) placebo recipients were assessed as having responded with a substantial reduction in their symptoms and recommencement of work, leisure, and social activities. The patients designated as having responded had improvement in physical, psychologic, and immunologic measures (p less than 0.01 for each).
CONCLUSION: Immunomodulatory treatment with immunoglobulin is effective in a significant number of patients with CFS, a finding that supports the concept that an immunologic disturbance may be important in the pathogenesis of this disorder.
PMID: 2146875 [PubMed - indexed for MEDLINE]
Deinen Einwänden vorzubeugen: Diese Zahlen sind erstens besser als alles andere, was Alternativtherapien zu bieten haben und die meisten Betroffenen hier im Forum wären froh darüber. Und zweitens werden Immunglobuline in Studien als Monotherapie eingesetzt. In der Praxis dringend notwendige ergänzende und die Erfolgsquote deutlich verbessernde Massnahmen verbietet das Studiendesign, um eindeutige Ergebnisse zu erzielen. Die positiven Ergebnisse sind daher sogar noch als suboptimal anzusehen.
